v3.26.1
Discontinued Operations - Schedule of Details of Loss from Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue [1]     $ (29,285)  
Income tax benefit (expense)     (39,200)  
(Loss) income from discontinued operations, net of tax $ (5,233) $ (15,786) 136,461 $ (18,449)
SomaScan Business        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue [2] 0 20,200 37,172 40,773
Cost of revenue 0 11,552 4,504 23,432
Selling, general and administrative expenses 0 8,216 6,055 17,099
Research and development 0 5,850 2,881 11,738
Transaction expenses 0 10,507 15,237 10,507
Total operating costs and expenses 0 36,125 28,677 62,776
Operating income (loss) 0 (15,925) 8,495 (22,003)
Other income, net 0 14 131 3,397
Gain on sale of business 0 0 172,289 0
Indemnification-related loss [3] (4,212) 0 (4,212) 0
(Loss) income from discontinued operations before income taxes (4,212) (15,911) 176,703 (18,606)
Income tax benefit (expense) (1,021) 125 (40,242) 157
(Loss) income from discontinued operations, net of tax $ (5,233) $ (15,786) $ 136,461 $ (18,449)
[1] Deferred revenue related to the Collaboration Agreement with Illumina was fully recognized upon the sale of the Disposed Entities. The Company has classified this revenue within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Please see Note 3, Discontinued Operations, for more information.
[2] During the six months ended June 30, 2026, the Company recognized revenue of $29.8 million related to the transaction price under the Collaboration Agreement with Illumina, which primarily reflects the release of the deferred revenue balance previously established under the Collaboration Agreement upon the sale of the SomaScan Business. The Company has classified the $29.8 million within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Out of the $29.8 million recognized, $0.6 million reflects Illumina’s exercise of its material right to be provided with SOMAmer reagents for commercialization of the co-branded kits.
[3] In connection with the sale of SomaLogic to Illumina, the Company agreed to indemnify Illumina for certain litigation matters. The Company recorded a liability of $3.3 million as of the closing date, which remained unchanged as of March 31, 2026. During the three months ended June 30, 2026, the Company recorded an additional charge of $4.2 million related to the litigation matters, which were settled in July 2026.